Monthly Archives: November 2011 - For Patients. By Patients - Stop Atrial Fibrillation

Apixaban (Eliquis) prevents more atrial fibrillation strokes than warfarin — March FDA approval expected

A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …

Read More
American Heart Association Scientific Sessions 2011

Women Have Different Atrial Fibrillation Ablation Results from Men — Video Interview with Dr. John Mandrola

At the American Heart Association Scientific Sessions 2011, Dr. John Mandrola presented a poster on gender-specific results of atrial fibrillation ablation in a private practice setting. In this video interview with him about the poster, he mentioned that in his experience women appear to be more challenging to treat with atrial fibrillation ablation and do …

Read More
Dr. Walid Saliba, Cleveland-Clinic

View the Transcript of our October Atrial Fibrillation Chat with Cleveland Clinic Afib Experts

Recently partnered with the Cleveland Clinic to give you an opportunity to chat live with two of their atrial fibrillation experts, Dr. Walid Saliba and Dr. David Van Wagoner, who were joined by founder Mellanie True Hills. The transcript of our afib community chat with these atrial fibrillation experts from the Cleveland Clinic …

Read More - For Patients. By Patients - Stop Atrial Fibrillation

FDA Panel Says Bipolar Radiofrequency Surgical Ablation Effective for Persistent Atrial Fibrillation

An FDA advisory panel voted that the overall benefits outweighed the risks in afib ablations using the AtriCure Synergy bipolar radiofrequency clamp. This was based on the results of the ABLATE clinical trial for ablation of persistent or longstanding persistent atrial fibrillation during other heart surgery. The panel recommended that the FDA approve it, setting …

Read More

FDA Approves Alternative to Warfarin — Rivaroxaban (Xarelto) Approved for Atrial Fibrillation Stroke Prevention

The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …

Read More